NCT05284994 - TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

June 30, 2024

Conditions

Nonsmall-cell Lung Cancer

Interventions

DRUG

TQ-B3525 Tablets, Osimertinib Mesylate Tablets

TQ-B3525 is a novel α/δ dual inhibitor PI3K kinase inhibitor. Osimertinib mesylate is a third-generation epidermal growth factor receptor inhibitor.

Trial Locations (9)

RECRUITING

Sun-Yat-Sen University Cancer Center, Guangzhou

RECRUITING

Sun Yat-Sen Memorial Hospital, Guangzhou

RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

RECRUITING

Affiliated Hospital Of Guangdong Medical University, Zhanjiang

RECRUITING

The Second People's Hospital of Guangdong Province, Guanzhou

RECRUITING

Southern Hospital of Southern Medical University, Guangzhou

RECRUITING

The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou

RECRUITING

Meizhou People's Hospital, Meizhou

RECRUITING

Jiangmen Central Hospital, Jiangmen